openPR Logo
Press release

Chronic Lymphocytic Leukemia Market Segmentation Outlook to 2026: Analysis by Type, Drug Type, Opportunity & Revenue Gain Idea by F. Hoffman-La Roche, AbbVie, Teva Pharmaceuticals, Gilead Sciences

02-08-2019 02:03 PM CET | Health & Medicine

Press release from: Future Market Insights

Chronic Lymphocytic Leukemia Market Segmentation Outlook

Chronic lymphocytic leukemia (CLL) is a blood and bone marrow disease that usually gets adverse slowly. It is one of the most common types of leukemia in adults. Chronic lymphocytic leukemia is a type of cancer in which the bone marrow makes too many lymphocytes.It may affect red blood cells, white blood cells, and platelets. Chronic lymphocytic leukemia is the second most common cancer in adult males. About 90% of chronic lymphocytic leukemia is diagnosed in middle age. Incidence rate of CLL is high in men and women over 50 years of age or middle age. It is rarely seen in people under age 40, and is extremely rare in children. In CLL, majority of the blood stem cells become abnormal lymphocytes healthy white blood cells. The abnormal lymphocytes may also be called leukemia cells. These abnormal lymphocytes are not able to fight infection very well. Also, as the number of lymphocytes increases in the blood and bone marrow, there is less room for healthy white blood cells, red blood cells, and platelets. This may cause infection, anemia, and easy bleeding which may result in death. In 2016, American Cancer Society has estimated that in the United States about18,960 new cases of chronic lymphocytic leukemia (CLL)and approximately 4,660 deaths by CLL are observed up till now.

Chronic Lymphocytic Leukemia Market: Drivers and Restraints

Increase in aging population is an impetus for the growth of the CLL market. The increasing incidences of cancers in developed and developing countries such as India, and Brazil are expected to boost market growth. Moreover, exceptional regulatory designations offered to certain drugs. CLL is a disease which affects a minute percentage of the population, that’s why they are treated by a few marketed drugs only.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-2481

A small or medium number of patients creates a very small market for these drugs. So it may or may not be profitable for companies to develop these drugs as recovering the research and developments of the drug expenses would be difficult. That’s why collaboration agreements and co-development are some of the key strategies adopted by top market players. For example, recently GlaxoSmithKline plc and Genmab A/S, have entered into co-development and collaboration agreement for drug Arzerra (ofatumumab), used in the treatment of relapsed CLL. Other two important drivers for CLL treatment market are family history of blood disorders and excessive exposure to harmful chemicals. Another trend that is expected to inspire market growth is a rise in the development of combination of drug therapies. Combination therapies for the treatment of CLL were available only in the form of chemotherapy combination drugs. Previously approved combinations were only few.However, stringent regulatory guidelines are expected to hamper market growth. Moreover, the high overall treatment cost for the therapy is another factor inhibiting the market growth. For example, GA101/RG7159 was launched in the market in 2014 by Genentech Inc (U.S.). The drug costs approximately at $409,580 for patients who take them annually.

Chronic Lymphocytic Leukemia Market: Segmentation

The global chronic lymphocytic leukemiamarket is classified on the basis of type, route of administration, type of drug, end user.

Based on type, the global chronic lymphocytic leukemiamarket is segmented into the following:

Acute myeloid (or myelogenous) leukemia (AML)
Chronic myeloid (or myelogenous) leukemia (CML)
Acute lymphocytic (or lymphoblastic) leukemia (ALL)
Chronic lymphocytic leukemia (CLL)

Based on Drug Route Administration (ROA) the global chronic Lymphocytic Leukemiamarket is segmented into the following:

Oral
Parenteral

Based on types of chemo drugs used the global chronic lymphocytic leukemiamarket is segmented into the following:

Purine analogs.
Alkylating agents
Corticosteroids
Other drugs

Based on end user global chronic lymphocytic leukemiamarket is segmented into the following:

Hospitals
Private Clinics
Diagnostic Laboratories
Research Laboratories
Research Institutes
Drug Store

Chronic Lymphocytic Leukemia Market overview:

Conventionally, the CLL therapeutics market is dominated by the parenteral segment. In the parenteral ROA, the drug is administered by the intravenous, subcutaneous, intrathecal, or intramuscular routes. But slowly oral drugs are expected to capture vast market share. Drugs delivered by oral route are absorbed rapidly and the onset of action is fast. Moreover, oral ROA is essential during emergencies when there is a need for greater patient compliance.

For example: - Imbruvica, rituximab, idelalisib are oral tablets given to CLL patients alone or in combination. The efficacy of ibrutinib (Imbruvica) and idelalisib (Zydelig) in chronic lymphocytic leukemia (CLL) suggests the drugs could potentially replace chemoimmunotherapy completely for some patients.

Chronic Lymphocytic Leukemia Market: Regional Overview

Region wise, the global chronic lymphocytic leukemiamarket is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America dominated the global market for chronic lymphocytic leukemiadue to good reimbursement policies for diagnostic, therapeutic procedures and number of government organizations investigating the efficiency. After North America this market is followed by Europe due to increase in the number of patients suffering from CLL. Asia Pacific region is expected to perceive a significantly faster growth over the forecast period due to a number of branded drugs will become available over the next four years, with the expanding patient pool receiving greater access to such new treatments.

Request to View TOC @ https://www.futuremarketinsights.com/toc/rep-gb-2481

Chronic Lymphocytic Leukemia Market: Key Players

Some of the key players in the market of near patient molecular solution are F. Hoffman-La Roche, AbbVie, Teva Pharmaceuticals, Gilead Sciences, Novartis, and Johnson & Johnson.

ABOUT US:
Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India.
FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

Future Market Insights
U.S. Office
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email: sales@futuremarketinsights.com
Web: https://www.futuremarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Chronic Lymphocytic Leukemia Market Segmentation Outlook to 2026: Analysis by Type, Drug Type, Opportunity & Revenue Gain Idea by F. Hoffman-La Roche, AbbVie, Teva Pharmaceuticals, Gilead Sciences here

News-ID: 1573154 • Views:

More Releases from Future Market Insights

Global Anesthesia Equipment Market to Reach USD 18.2 Billion by 2035
Global Anesthesia Equipment Market to Reach USD 18.2 Billion by 2035
The Anesthesia Equipment Market is witnessing robust growth, with its value estimated at USD 9.3 billion in 2025 and projected to nearly double to USD 18.2 billion by 2035. This growth trajectory represents a compound annual growth rate of 7.0%, driven by increasing surgical volumes, rising prevalence of chronic respiratory and cardiovascular disorders, and ongoing expansion of healthcare infrastructure. The market is undergoing transformative change, as both established manufacturers and
Intravascular Ultrasound Systems Market to Reach USD 1455.7 Million by 2035
Intravascular Ultrasound Systems Market to Reach USD 1455.7 Million by 2035
The intravascular ultrasound (IVUS) systems market is on track to record consistent growth over the next decade. Valued at USD 893.7 million in 2025, the market is expected to expand to USD 1455.7 million by 2035, reflecting a compound annual growth rate of 5.0%. With cardiovascular disease remaining one of the leading causes of mortality globally, the demand for advanced intravascular imaging technologies is escalating. IVUS systems, which provide real-time
Electric Power Sports Market to Reach USD 18.5 Billion by 2035
Electric Power Sports Market to Reach USD 18.5 Billion by 2035
The global Electric Power Sports Market is on a fast track to transformation, as consumers, manufacturers, and policymakers align on one powerful goal: sustainable, high-performance recreational experiences. Valued at USD 10.3 billion in 2025, the market is projected to expand to USD 18.5 billion by 2035, reflecting a steady compound annual growth rate (CAGR) of 6.0%. This momentum is set to generate an absolute dollar opportunity of USD 8.2 billion over
Hair Straightener Market Forecast to Reach USD 12.4 Billion by 2035 as Innovation and Consumer Demand Drive Growth
Hair Straightener Market Forecast to Reach USD 12.4 Billion by 2035 as Innovatio …
The global hair straightener market is entering a transformative growth phase, as industry leaders and emerging brands alike innovate to meet rising consumer demand for advanced hair styling solutions. Valued at USD 7.1 billion in 2025, the market is projected to reach USD 12.4 billion by 2035, registering a compound annual growth rate (CAGR) of 5.7% over the forecast period. Between 2025 and 2030, the market is set to rise steadily

All 5 Releases


More Releases for CLL

Expanding Market for Chronic Lymphocytic Leukemia (CLL) Driven by Rising Cancer …
The global chronic lymphocytic leukemia (CLL) market size was USD 10.00 Billion in 2022 and is expected to register a revenue CAGR of 7.8% during the forecast period. A detailed market analysis reveals significant growth in the Chronic Lymphocytic Leukemia (CLL) sector, fueled by a surge in cases of blood cancers, ongoing research advancements, and innovative treatments. This report offers insights into the factors driving revenue, evolving therapeutic options, and
Chronic Lymphocytic Leukemia (CLL) Treatment Market Expected to Deliver Dynamic …
This Report by Worldwide Market Reports on Chronic Lymphocytic Leukemia (CLL) Treatment Market 2023 is a detailed analysis of the market providing you with the latest industry data and future market trends. The details and data in the report will allow you to identify three important factors in the market which are products, revenue, and growth profitability. The Chronic Lymphocytic Leukemia (CLL) Treatment market offers company profiling, product specifications, sales,
Pruritus Drugs Market Exclusive insight on Transformation 2028 | Granulomatosis …
Global Pruritus Drugs Market: Overview Transdermal drug delivery system is the most preferred way to inject pruritus drugs. Most of the pruritus drugs that are available in the market are in the semi-solid topical dosage state. It includes forms such as creams, gels, and lotions. These products are quite easy to apply, give no or less pain, and are quicker in terms of delivering desired effect as compared to other drug
Therapeutics Development of Chronic Lymphocytic Leukemia (CLL) - Pipeline Review …
ResearchMoz added Latest Research Report titled " Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017 " to it's Large Report database. Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2017, provides an overview of the Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape. Chronic lymphocytic leukemia (CLL) is a type of cancer that starts
Global Chronic Lymphocytic Leukemia (CLL) Therapeutics Devices Market 2017 F. Ho …
Chronic Lymphocytic Leukemia (CLL) Therapeutics Devices Market Research Report A market study based on the " Chronic Lymphocytic Leukemia (CLL) Therapeutics Devices Market " across the globe, recently added to the repository of Market Research, is titled ‘Global Chronic Lymphocytic Leukemia (CLL) Therapeutics Devices Market 2017’. The research report analyses the historical as well as present performance of the worldwide Chronic Lymphocytic Leukemia (CLL) Therapeutics Devices industry, and makes predictions
Global CLL Therapeutics Market To Grow At A CAGR Of 19.16% During The Period 201 …
Researchmoz added Most up-to-date research on "Global Chronic Lymphocytic Leukemia market 2016-2020" to its huge collection of research reports. Cancer that starts from the hematopoietic stem cells of the bone-marrow is referred to as leukemia. Leukemia can be chronic or acute depending on the maturity of the cells. In addition, based on the bone marrow cells from which the cancer starts, leukemia can be categorized as lymphocytic or myeloid. Hence, leukemia